Dr. Sara Maria Garrido, MD

Dr. Garrido practices at Baptist Health Baptist Hospital in Miami, Florida, part of Baptist Health South Florida.

Dr. Garrido's NPI, 1245227594, was assigned on October 3, 2005. Dr. Garrido graduated from Universidad del Valle Health Sciences in 1988. Dr. Garrido holds Florida license ME63394.

Dr. Garrido's primary practice is Baptist Health Baptist Hospital, at 8900 N Kendall Dr, Miami, FL 33176 in Miami-Dade County. The practice phone is (786) 596-1960.

Dr. Garrido's primary practice is Baptist Health Baptist Hospital in Miami, Florida, part of Baptist Health South Florida. Dr. Garrido is also affiliated with South Miami Hospital. The medical group on file is Baptist Health Medical Group Oncology. Dmand AI also links Dr. Garrido to 3 more hospitals and 1 breast imaging center, each named with a free account.

Dmand AI tracks the electronic health record (EHR) system at each site where Dr. Garrido practices, 6 sites in all. Vendor and product names are available with a free account.

Hematology and oncology is Dr. Garrido's primary specialty in the NPI Registry, under taxonomy code 207RH0003X. Dr. Garrido is board certified in medical oncology by the American Board of Internal Medicine. Dr. Garrido is licensed in Florida.

Dmand AI lists breast cancer, chronic anemia, chronic leukemia, lung cancer and multiple myeloma among the conditions Dr. Garrido treats.

CMS data shows 496 Medicare services from Dr. Garrido across 5 procedure codes in 2024, for 271 Medicare patients. Medicare paid $40,844 for them.

CMS counts 271 Medicare patients who saw Dr. Garrido in 2024. The largest group is 65 to 74, with 114 patients. 75% of them have cancer, and 75% have high blood pressure. 24% are also on Medicaid. Their average risk score is 1.81, where 1.00 is the Medicare average, so they are sicker than most Medicare patients.

Across all payers, Dmand AI patient panel data puts Dr. Garrido's median patient age at 65, with 96% women.

In 2024, Dr. Garrido wrote 765 Medicare Part D claims for 236 patients. 81% of them were for generic drugs. CMS names the drug for 592 of them, across 9 drugs with 11 or more claims each, at $339,664 in total drug cost. In 2023, CMS named 1,176 claims across 21 drugs.

CMS publishes a Merit-based Incentive Payment System (MIPS) score of 93 out of 100 for Dr. Garrido for performance year 2024, reported as part of a group. Dr. Garrido accepts Medicare assignment, so Medicare's approved amount is taken as full payment. CMS lists Dr. Garrido as offering telehealth.

Dmand AI links 6 papers to Dr. Garrido in 2022. The most frequent topics are Apoptosis, Proliferating Cell Nuclear Antigen and Proto-Oncogene Proteins c-bcl-2. Dr. Garrido has published most often in Leuk Res. Dr. Garrido's most frequent co-authors are Federico Albrecht, MD, Santiago Aparo, MD and John Paul Diaz, MD.

Dmand AI links Dr. Garrido to 1 clinical trial. 1 is still active or recruiting. Conditions studied include Carcinoma, Intraductal, Noninfiltrating and Breast Carcinoma In Situ.

CMS Open Payments shows 25 general payments to Dr. Garrido from 10 drug and device companies from 2016 to 2025. Consulting fees make up the largest share, 70% of the total. Pfizer Inc. paid the most, $2,146.

Dmand AI lists 2 awards for Dr. Garrido.

Dr. Garrido graduated from Universidad del Valle Health Sciences in 1988. Dr. Garrido is a member of ASCO.

Dr. Garrido is in network with 13 carriers, including Elevance, Aetna and Blue Cross Blue Shield of Michigan. Medicare plans come from the most carriers, 10. Check the plan with the practice before a visit.